Proactive Investors - Run By Investors For Investors

Summit Therapeutics advancing its pipeline of innovative antibiotics

Summit Therapeutics PLC’s (NASDAQ:SMMT) (LON:SUMM) Dr Richard Pye updates Proactive London soon after taking their next-generation antibiotic into the final and decisive stage of clinical trials.

The Phase III study of ridinilazole began last month (February).

Summit's also busy developing its pre-clinical candidate for gonorrhoea.

 
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use